Icon Plc (NASDAQ:ICLR) had its target price increased by Mizuho from $104.00 to $108.00 in a report released on Thursday morning, Marketbeat Ratings reports. Mizuho currently has a neutral rating on the medical research company’s stock.

A number of other equities research analysts also recently weighed in on ICLR. ValuEngine downgraded shares of Icon Plc from a buy rating to a hold rating in a report on Wednesday, May 31st. BidaskClub downgraded shares of Icon Plc from a strong-buy rating to a buy rating in a report on Friday, June 16th. Evercore ISI upped their price target on shares of Icon Plc from $91.50 to $92.00 and gave the company an outperform rating in a report on Friday, April 28th. Goldman Sachs Group, Inc. (The) raised shares of Icon Plc from a buy rating to a conviction-buy rating and set a $117.00 price target for the company in a report on Friday, July 7th. Finally, Zacks Investment Research downgraded shares of Icon Plc from a hold rating to a sell rating in a report on Wednesday, April 26th. Three investment analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the stock. The stock presently has a consensus rating of Buy and a consensus price target of $102.63.

Icon Plc (NASDAQ ICLR) traded up 2.12% during trading on Thursday, reaching $105.02. 633,241 shares of the company’s stock traded hands. Icon Plc has a 12 month low of $73.76 and a 12 month high of $109.32. The stock has a market capitalization of $5.68 billion, a P/E ratio of 21.30 and a beta of 0.59. The company has a 50-day moving average of $97.95 and a 200 day moving average of $87.43.

Icon Plc (NASDAQ:ICLR) last posted its quarterly earnings data on Thursday, July 27th. The medical research company reported $1.31 earnings per share for the quarter, topping the consensus estimate of $1.30 by $0.01. Icon Plc had a net margin of 15.97% and a return on equity of 28.72%. The business had revenue of $431 million during the quarter, compared to the consensus estimate of $430.68 million. During the same quarter in the prior year, the company posted $1.14 earnings per share. The company’s quarterly revenue was up 5.0% compared to the same quarter last year. On average, equities research analysts expect that Icon Plc will post $5.23 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This news story was posted by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The original version of this news story can be viewed at https://www.watchlistnews.com/mizuho-raises-icon-plc-iclr-price-target-to-108-00/1464512.html.

Hedge funds have recently bought and sold shares of the stock. Somerset Trust Co raised its stake in Icon Plc by 0.4% in the first quarter. Somerset Trust Co now owns 5,638 shares of the medical research company’s stock worth $449,000 after buying an additional 24 shares in the last quarter. Farmers & Merchants Investments Inc. raised its stake in Icon Plc by 11.5% in the first quarter. Farmers & Merchants Investments Inc. now owns 51,236 shares of the medical research company’s stock worth $4,085,000 after buying an additional 5,269 shares in the last quarter. Legato Capital Management LLC raised its stake in Icon Plc by 7,872.0% in the first quarter. Legato Capital Management LLC now owns 6,078,411 shares of the medical research company’s stock worth $76,247,000 after buying an additional 6,002,164 shares in the last quarter. Cim LLC raised its stake in Icon Plc by 4.6% in the first quarter. Cim LLC now owns 6,095 shares of the medical research company’s stock worth $486,000 after buying an additional 270 shares in the last quarter. Finally, Atria Investments LLC purchased a new stake in Icon Plc during the first quarter worth approximately $214,000. 92.39% of the stock is owned by institutional investors.

Icon Plc Company Profile

ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.

Analyst Recommendations for Icon Plc (NASDAQ:ICLR)

Receive News & Ratings for Icon Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon Plc and related companies with Analyst Ratings Network's FREE daily email newsletter.